A groundbreaking randomized, double-blind study conducted at Karolinska Institutet in Sweden has brought new hope to the treatment of depression, showcasing the rapid antidepressant effects of a single dose of psilocybin, a psychedelic compound found in so-called “magic mushrooms.” Published in JAMA Network Open, this phase 2 clinical trial demonstrated that psilocybin can significantly alleviate symptoms in individuals suffering from moderate to severe recurrent depression, with effects manifesting within days and persisting for several months. This study is among the first to assess the efficacy of psilocybin in typical depression cases, expanding the scope beyond the previously examined cancer-related or treatment-resistant depression.
Depression remains a debilitating global health issue affecting millions and imposing significant social and economic burdens. Traditional antidepressants—in particular, selective serotonin reuptake inhibitors (SSRIs)—have long been the treatment mainstay but suffer from delayed onset of action, typically requiring weeks before symptom relief is observed, and many patients experience limited efficacy or adverse effects. Psilocybin’s potential as a fast-acting antidepressant offers a paradigm shift in psychiatric care, leveraging its unique pharmacological profile to target depressive symptomatology more directly.
In the Karolinska Institutet trial, 35 participants between the ages of 20 and 65 with confirmed moderate to severe depression were randomly assigned to receive either a single 25 mg oral dose of psilocybin or an active placebo, niacin, which provokes discernible physiological effects but lacks psychoactive properties. Both groups underwent therapeutic support sessions before, during, and after treatment to maximize safety and facilitate psychological processing of the experience. The psilocybin was administered under controlled conditions, where subjects reclined with eye masks and headphones playing curated music, an approach designed to enhance the inward focus and therapeutic setting.
Efficacy was primarily measured using the Montgomery–Åsberg Depression Rating Scale (MADRS), a clinician-administered scale ranging from 0 to 60 points that gauges depression severity. Baseline eligibility required a minimum MADRS score of 22, categorizing participants as moderately to severely depressed. Impressively, by day eight post-treatment, the psilocybin group exhibited an average reduction of 9.7 points on the MADRS, significantly outperforming the placebo’s 2.4-point improvement. This 7.3-point differential not only achieved statistical significance but also meets clinical criteria indicative of meaningful depression alleviation. Remarkably, these antidepressant effects remained robust through days 15 and 42.
Self-reported MADRS scores parallelled clinician assessments, revealing that subjects perceived improvements as early as day two following the psilocybin dose. These subjective benefits endured for over three months, underscoring psilocybin’s potential for sustained symptom relief. Furthermore, remission rates revealed a substantial advantage for psilocybin, with 53% of treated individuals reaching remission six weeks post-dosing compared to just 6% in the placebo cohort. Although the remission difference diminished at the one-year mark—owing to natural recovery within the placebo group—the early rapid response remains clinically significant.
The study’s lead author, Dr. Hampus Yngwe, highlighted the promise of psilocybin as an alternative to conventional antidepressants, particularly in scenarios where quick symptom resolution is paramount. Nonetheless, the research team advises caution, noting that long-term outcomes remain unclear and that multiple administrations might be necessary to sustain remission and prevent relapse. These findings open avenues for future investigations assessing the optimal dosing frequency and long-term management with psychedelic-assisted therapy.
Safety profiles were generally favorable; most adverse effects were transient and mild to moderate in intensity. However, two psilocybin recipients experienced severe and enduring anxiety post-treatment, necessitating clinical intervention. These incidents emphasize the indispensable role of thorough screening and robust therapeutic oversight when administering psychedelic compounds. Professor Johan Lundberg, who spearheaded the study, stressed that while promising, psilocybin treatment is not without risks and requires careful patient selection and monitoring.
Blinding remains a methodological hurdle in psychedelic clinical trials due to the vivid and distinctive effects elicited by compounds like psilocybin, making true double-blinding difficult. In this study, most participants accurately guessed their treatment allocation, revealing issues in separating pharmacological effects from expectation biases. This recognition urges cautious interpretation of the data and advocates for developing novel trial designs to better control for placebo and expectancy influences.
Further research is underway to elucidate the neurobiological mechanisms underpinning psilocybin’s antidepressant effects. The investigators are currently analyzing positron emission tomography (PET) imaging and biomarkers from blood and cerebrospinal fluid collected pre- and post-treatment. It is hypothesized that psilocybin may promote synaptic plasticity by enhancing synapse density and connectivity in brain regions implicated in mood regulation. Preclinical studies align with this concept, demonstrating psychedelic-induced stimulation of neuroplastic processes, which could counteract the synaptic deficits observed in depression.
This study represents a significant stride in psychopharmacology, corroborating the therapeutic potential of psychedelics for common depressive disorders while simultaneously delineating their limitations and safety considerations. With mental health care in urgent need of innovative interventions, this research paves the way for integrating psychedelics as viable adjuncts or alternatives to existing treatments, provided that future large-scale studies confirm their efficacy and safety profiles.
Conducted in collaboration between Karolinska Institutet and the Brain Stimulation Clinic within Northern Stockholm Psychiatry, the research was financially supported by Norrsken Mind and the Swedish Research Council. Ethical transparency was maintained throughout, with Professor Lundberg disclosing a personal honorarium from Janssen-Cilag. The comprehensive findings from this study promise to ignite further scientific inquiry and invigorate clinical innovation in tackling one of the most pervasive disorders of modern society.
Subject of Research: People
Article Title: Acute and Late Effects of Psilocybin on Symptoms in Major Depression: a randomised clinical trial
News Publication Date: 15-May-2026
Web References: http://dx.doi.org/10.1001/jamanetworkopen.2026.12589
Image Credits: Photo by Stefan Zimmerman
Keywords: Depression, Psilocybin, Psychedelic Therapy, Clinical Trial, Major Depression, Rapid Antidepressant Effects, Neuroplasticity, Psychiatric Disorders, Mental Health
Tags: fast-acting antidepressants researchJAMA Network Open psilocybin studyKarolinska Institutet depression trialmagic mushrooms depression treatmentmoderate to severe recurrent depressionnovel psychiatric treatments depressionphase 2 clinical trial psilocybinpsilocybin antidepressant effectspsilocybin vs SSRIs efficacypsychedelic therapy for depressionrapid depression treatmentsingle dose psilocybin study
